Myositis ossificans progressiva, ankle, foot and toe(s)
ICD-10 M61.17 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, ankle, foot and toe(s).
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues. This condition typically begins in early childhood and progresses over time, leading to significant muscle weakness and restricted mobility. In the case of M61.17, the ossification occurs specifically in the ankle, foot, and toe regions, which can severely impact a patient's ability to walk and perform daily activities. The condition is caused by mutations in the ACVR1 gene, which plays a crucial role in bone growth and development. Patients may experience episodes of swelling, pain, and stiffness in the affected areas, often triggered by minor injuries or physical activity. Diagnosis is primarily clinical, supported by imaging studies that reveal abnormal bone formation. Management focuses on symptomatic relief and physical therapy, as surgical interventions can exacerbate the condition. Understanding the complexities of MOP is essential for accurate coding and appropriate patient care.
Detailed clinical history, including onset, progression, and treatment response.
Patients presenting with unexplained muscle stiffness and swelling.
Ensure genetic testing results are documented to support diagnosis.
Imaging studies showing ossification and detailed surgical history if applicable.
Patients requiring surgical intervention for mobility issues.
Document any exacerbation of symptoms post-surgery.
Used for follow-up visits to monitor MOP symptoms.
Document patient history, examination findings, and treatment plan.
Rheumatology and orthopedics may require additional details on functional status.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues, leading to progressive disability.
Diagnosis is based on clinical evaluation, imaging studies, and genetic testing to confirm mutations in the ACVR1 gene.
Common symptoms include muscle weakness, stiffness, and episodes of swelling in the affected areas.
Management focuses on physical therapy, pain management, and avoiding surgical interventions that may exacerbate the condition.
